NCT06378346

GU-01: Glycyrrhizin in Prostate Cancer

GU-01: Glycyrrhizin in Prostate Cancer: A Window-of-Opportunity Trial

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: University of Illinois at Chicago · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a pilot, randomized, window-of-opportunity treatment trial in which participants with previously untreated prostate cancer (PCa) who are candidates for surgery (radical prostatectomy)

Detailed description

This is a pilot, randomized, window-of-opportunity treatment trial in which participants with previously untreated prostate cancer who are candidates for surgery (radical prostatectomy) will receive one cycle of therapy consisting of Glycyrrhizin (GLY) (Observation, Dose Level 1 75mg daily, or Dose Level 2, 150mg daily) for 5 weeks (+/- 2 weeks) prior to surgery.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
OTHER	Observation	Participants will not receive glycyrrhizin
DRUG	Glycyrrhizin - 75 mg	Participants will either receive 75 mg orally daily
DRUG	Glycyrrhizin - 150 mg	Participants will receive 150 mg orally daily

Timeline

• Start date: 2024-07-25
• Primary completion: 2027-03-01
• Completion: 2027-03-01
• First posted: 2024-04-22
• Last updated: 2026-02-23

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study